Egetis Therapeutics AB EGTX

First and only FDA-approved treatment of peripheral thyrotoxicosis in adults and pediatric patients with monocarboxylate transporter 8 (MCT8) deficiency in the United StatesEgetis launches Egetis RareLink™, the EMCITATE patient support program, in partnership with PANTHERx® RareFDA granted Egetis a Rare Pediatric Disease Priority Review Voucher (PRV) in connection with the approval Egetis to host a conference call and webcast for analysts and investors on Tuesday September 29 at 8:00 am CEST (2:

Bristol Myers Squibb and Egetis await FDA decisions on treatments for heart and rare genetic conditions, while Scholar Rock, Biofrontera and Mirum have already secured regulatory wins ahead of schedule.

STOCKHOLM, SWEDEN, Sept. 03, 2026. (GLOBE NEWSWIRE) Egetis Therapeutics AB (publ) (“Egetis” or the “Company”) (NASDAQ Stockholm: EGTX) today announced that it will participate in upcoming investor conferences in September. Cantor Global Healthcare Conference 2026Date: Friday, September 11, 2026Location: Waldorf Astoria, New YorkFormat: Fireside chat and 1-1 meetings Nicklas Westerholm, CEO, will participate in a fireside chat, 9:10-9:40 a.m. EDT (15:10-15:40 CEST). A live webcast and replay will

Revenue grows 23% year-over-year as company strengthens cash position ahead of potential Q4 2026 US launch of Emcitate.

STOCKHOLM, SE / ACCESS Newswire / June 10, 2026 / Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (STO:EGTX)(Nasdaq Stockholm:EGTX), an innovative pharmaceutical company focused on late-stage development and commercialization of treatments ...

STOCKHOLM, SE / ACCESS Newswire / May 19, 2026 / Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (STO:EGTX)(NASDAQ Stockholm:EGTX) today announced its participation in the annual conference of the International Society for Pharmacoeconomics ...

STOCKHOLM, SE / ACCESS Newswire / May 7, 2026 / Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (Nasdaq Stockholm:EGTX) today announced that the Company is planning to participate in several upcoming medical conferences in 2026, including: ...

STOCKHOLM, SE / ACCESS Newswire / May 5, 2026 / Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (NASDAQ Stockholm:EGTX) today announced that the United States Patent and Trademark Office (USPTO) granted Patent No. US 12611383B1 for the Company's ...

STOCKHOLM, SE / ACCESS Newswire / April 30, 2026 / Egetis Therapeutics (STO:EGTX) - Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (NASDAQ Stockholm:EGTX), today announced its participation in the Pediatric Endocrine Society (PES) Annual ...

As European markets face a downturn, with the pan-European STOXX Europe 600 Index ending the week down 2.54% amid geopolitical tensions and economic uncertainties, investors are increasingly looking towards growth companies with significant insider ownership as potential opportunities. In this environment, stocks that combine robust growth prospects with high levels of insider investment can offer a compelling mix of confidence and alignment between company leadership and shareholders.

Despite a challenging financial quarter, Egetis Therapeutics AB (FRA:P0F) makes significant strides in drug development and market expansion.

As European markets face heightened geopolitical risks and economic uncertainties, traditionally defensive sectors have shown resilience amidst the volatility. In this environment, growth companies with substantial insider ownership can be particularly appealing, as they often signal strong internal confidence and alignment with shareholder interests.

As European markets navigate a challenging landscape marked by geopolitical tensions and economic uncertainties, the pan-European STOXX Europe 600 Index has seen a notable decline, with defensive sectors outperforming amid these headwinds. In this environment, growth companies with strong insider ownership can offer unique insights into business resilience and strategic direction, making them particularly intriguing for investors seeking stability and potential upside.

As geopolitical tensions and economic uncertainties weigh on European markets, with major indices like the STOXX Europe 600 experiencing notable declines, investors are increasingly turning their attention to companies with strong insider ownership. In this environment, growth companies where insiders hold significant stakes can offer a compelling proposition, as such ownership often signals confidence in the company's long-term prospects amidst broader market challenges.

As geopolitical tensions and economic uncertainties weigh on European markets, with the STOXX Europe 600 Index experiencing a notable decline, investors are increasingly seeking stability in growth companies with strong insider backing. In such an environment, stocks that exhibit robust growth potential coupled with high insider ownership can offer a compelling proposition due to the alignment of interests between shareholders and company insiders.

As the European markets face geopolitical uncertainties and economic challenges, with indices like the STOXX Europe 600 Index experiencing declines, investors are increasingly focusing on companies with strong insider ownership as a sign of confidence in their growth potential. In such an environment, stocks where insiders have significant stakes can be appealing to investors seeking alignment between management interests and shareholder value.

As European markets face challenges with geopolitical risks and economic uncertainties, traditionally defensive sectors have shown resilience while major indices like Germany's DAX and France’s CAC 40 have experienced declines. In this environment, growth companies with high insider ownership can offer a unique appeal to investors, as they often indicate strong management confidence and alignment of interests, which may be particularly valuable amidst the current market volatility.

As European markets experience a positive upswing, highlighted by gains in major indices like Germany’s DAX and France’s CAC 40, investors are closely monitoring the region's economic outlook amid geopolitical developments. In this environment, growth companies with substantial insider ownership can be particularly appealing as they often signal strong confidence from those closest to the business operations.

STOCKHOLM, SE / ACCESS Newswire / April 9, 2026 / Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (STO:EGTX), today announced the appointment of Tiago Nunes, MD, PhD, as Chief Medical Officer (CMO), effective May 1, 2026. Tiago Nunes is ...